These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 2021547)

  • 41. Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice.
    Arteaga CL; Carty-Dugger T; Moses HL; Hurd SD; Pietenpol JA
    Cell Growth Differ; 1993 Mar; 4(3):193-201. PubMed ID: 8466857
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The regulatory effect of tamoxifen on fibronectin expression in estrogen-dependent MCF-7 breast carcinoma cells.
    Horii Y; Takei H; Koibuchi Y; Horiguchi J; Maemura M; Iino Y; Morishita Y
    Oncol Rep; 2006 May; 15(5):1191-5. PubMed ID: 16596185
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance.
    Bates SE; Davidson NE; Valverius EM; Freter CE; Dickson RB; Tam JP; Kudlow JE; Lippman ME; Salomon DS
    Mol Endocrinol; 1988 Jun; 2(6):543-55. PubMed ID: 3047554
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators.
    Seymour L; Bezwoda WR
    Br J Cancer; 1993 Aug; 68(2):352-6. PubMed ID: 8347490
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
    Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
    Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transforming growth factors in human breast cancer.
    Salomon DS; Ciardiello F; Valverius E; Saeki T; Kim N
    Biomed Pharmacother; 1989; 43(9):661-7. PubMed ID: 2624883
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
    Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In situ analysis of transforming growth factors-beta (TGF-beta 1, TGF-beta 2, TGF-beta 3) and TGF-beta type II receptor expression in basal cell carcinomas.
    Schmid P; Itin P; Rufli T
    Br J Dermatol; 1996 Jun; 134(6):1044-51. PubMed ID: 8763422
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
    Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tamoxifen treatment failure in cancer and the nonlinear dynamics of TGFbeta.
    Turner S; A Sherratt J; Cameron D
    J Theor Biol; 2004 Jul; 229(1):101-11. PubMed ID: 15178188
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance.
    Johnston SR; Riddler S; Haynes BP; A'Hern R; Smith IE; Jarman M; Dowsett M
    Br J Cancer; 1997; 75(6):804-9. PubMed ID: 9062399
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cellular and humoral immunodeficiency in breast cancer patients resistant to hormone therapy.
    Zavadova E; Vocka M; Spacek J; Konopasek B; Fucikova T; Petruzelka L
    Neoplasma; 2014; 61(1):90-8. PubMed ID: 24195514
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor necrosis factor alpha enhances secretion of transforming growth factor beta2 in MCF-7 breast cancer cells.
    Danforth DN; Sgagias MK
    Clin Cancer Res; 1996 May; 2(5):827-35. PubMed ID: 9816237
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
    Osipo C; Gajdos C; Cheng D; Jordan VC
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer.
    Johnson RW; Merkel AR; Page JM; Ruppender NS; Guelcher SA; Sterling JA
    Clin Exp Metastasis; 2014 Dec; 31(8):945-59. PubMed ID: 25359619
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor beta 1 and its latent form binding protein in cultured breast carcinoma cells.
    Koli K; Keski-Oja J
    Cancer Res; 1995 Apr; 55(7):1540-6. PubMed ID: 7882362
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development and characterization of a tamoxifen-resistant breast carcinoma xenograft.
    Naundorf H; Becker M; Lykkesfeldt AE; Elbe B; Neumann C; Büttner B; Fichtner I
    Br J Cancer; 2000 Jun; 82(11):1844-50. PubMed ID: 10839300
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
    Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
    Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transition of human breast cancer cells from an oestrogen responsive to unresponsive state.
    Darbre PD; Daly RJ
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):753-63. PubMed ID: 2285587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.